an> (the "U.S. Prospectus") will be available on EDGAR at www.sec.gov
and a copy of the final prospectus supplement and accompanying base shelf prospectus relating to the Offering in Canada
(the "Canadian Prospectus") will be available on SEDAR at www.sedar.com
. Alternatively, a copy of the U.S. Prospectus may be obtained from Goldman, Sachs & Co. at 200 West Street, New York, New York
10282, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email: firstname.lastname@example.org
and a copy of the Canadian Prospectus may be obtained from Goldman Sachs Canada Inc. at 77 King Street West, Suite 3400, Toronto, Ontario
M5K 1B7, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email: email@example.com
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Forward Looking Statements
This press release may contain forward-looking statements, including, but not limited to those related to the Company's expectations in co
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Valeant Pharmaceuticals International, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Valeant Pharmaceuticals Announces Public Offering Of Common Shares2
. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus3
. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole4
. Valeant Pharmaceuticals Announces 2013 Annual Meeting Results5
. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference6
. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors7
. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders8
. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal9
. Valeant Pharmaceuticals Provides Efinconazole Update10
. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results11
. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel